Drug intelligence / Profile preview

telmisartan + s-amlodipine

Development stage
Phase 1
Lead developer
Chong Kun Dang Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Telmisartan + S-amlodipine is a fixed-dose combination of two antihypertensive agents used to treat high blood pressure (hypertension). Telmisartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the type 1 angiotensin II receptor in vascular smooth muscle and the adrenal gland, leading to vasodilation and reduced aldosterone secretion. S-Amlodipine is the S-enantiomer of amlodipine, a calcium channel blocker (CCB), which inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, resulting in relaxation of blood vessels. The combination provides better blood pressure control than either agent alone by targeting different mechanisms involved in hypertension[1][2][5]. This therapy reduces cardiovascular risk associated with uncontrolled hypertension.

Brand names
TwynstaEspin TMAmtmIldomex-TMTelmela AMPressault AMTelx AM
Other names
telmisartan + s-amlodipines-amlodipine + telmisartan
02

Targets

LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on telmisartan + s-amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on telmisartan + s-amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call